Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

 
• By Jessica Merrill
Businessman
Remicade biosimilar case reveals cavernous market challenges • Source: Shutterstock

More from Drug Pricing

More from Scrip